By Turna Ray

AstraZeneca announced earlier this month that it will not seek approval from the US Food and Drug Administration for its EGFR tyrosine kinase inhibitor Iressa as a treatment for non-small cell lung cancer.

"AstraZeneca does not plan to pursue approval for Iressa in the US," the company said in a statement. Furthermore, AstraZeneca has informed the FDA that it will be withdrawing its accelerated approval new drug application for Iressa as of Sept. 30.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.